Walmart starts selling Peptonic's products in the US

Peptonic Medical AB (publ) ("Peptonic") announced today that the company has agreed with the world's largest retail chain Walmart to begin selling Peptonic's self-test for bacterial vaginosis.

The US is an important market. It is very gratifying that Walmart has decided to sell our patented self-test for bacterial vaginosis," says Erik Sundquist, CEO of Peptonic Medical.

"Increasing the distribution of our products is an important part of our strategy, which makes this agreement with the world's largest retail chain Walmart extra positive and also shows that the need for our products is great. It paves the way for rapid growth in what is already our largest market today," says Erik Sundquist.

The distribution agreement with Walmart, which has approximately 10,500 stores worldwide, of which just under 5,000 are in the United States, primarily applies to Peptonic's patented self-test for diagnosing bacterial vaginosis. The test will be sold under Walmart's own brand. What makes the test unique is the combination of high precision and immediate results.

The distribution agreement applies to the United States and Walmart is now conducting an overview of stores currently for distribution.

In Peptonic's American organization, since the beginning of summer 2023, Angella Garcia is responsible for retail chains. Angella has extensive experience in sales to these channels in the US, but also in medtech. Through the agreement with Walmart, there is also a dialogue about the distribution of a further selection of Peptonic's current and future products. Pharmiva's product Vernivia will be an excellent and unique treatment solution for the self-test for bacterial vaginosis.

Peptonic expects the agreement to have a positive impact on the company's sales from 2024.